<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423694</url>
  </required_header>
  <id_info>
    <org_study_id>2012BAI24B01</org_study_id>
    <nct_id>NCT02423694</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Electro-acupuncture for Mild-to-moderate Perimenopausal Depression</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial Hospital of Traditional Chinese Medicine</source>
  <brief_summary>
    <textblock>
      Main objective: to compare the effects of electro-acupuncture and escitalopram oxalate
      tablets on mild-to-moderate perimenopausal depression, and to evaluate the safety of
      electroacupuncture stimulation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in scores of the 17-item Hamilton depression rating scale (HAMD-17)</measure>
    <time_frame>0 week, 4th week, 8th week, 12th week, 16th week and 24th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in scores of the Menopause-Specific Quality of Life questionnaire (MENQOL)</measure>
    <time_frame>0 week, 4th week, 8th week, 12th week, 16th week, 20th week and 24th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in level of estradiol (E2),</measure>
    <time_frame>0 week, 12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in level of follicle-stimulating hormone (FSH)</measure>
    <time_frame>0 week, 12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in level of Luteinizing hormone (LH)</measure>
    <time_frame>0 week, 12th week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in level of FSH/LH</measure>
    <time_frame>0 week, 12th week</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>safety of electro-acupuncture as measured by safety and acceptability questionnaires</measure>
    <time_frame>0 week, 4th week, 8th week, and 12th week</time_frame>
    <description>safety and acceptability</description>
  </other_outcome>
  <other_outcome>
    <measure>safety of escitalopram as measured by Asberg Rating Scale for Side Effect (SERS)</measure>
    <time_frame>0 week, 4th week, 8th week, and 12the week</time_frame>
    <description>Asberg Rating Scale for Side Effect (SERS)</description>
  </other_outcome>
  <other_outcome>
    <measure>safety of escitalopram as measured by liver functure test</measure>
    <time_frame>0 week, 4th week, 8th week, and 12the week</time_frame>
    <description>ALT, aspartate transminase (AST), and TBIL</description>
  </other_outcome>
  <other_outcome>
    <measure>safety of escitalopram as measured by kidney functure test</measure>
    <time_frame>0 week, 4th week, 8th week, and 12the week</time_frame>
    <description>Cr, BUN</description>
  </other_outcome>
  <other_outcome>
    <measure>safety of both groups before treatment as measured by EKG</measure>
    <time_frame>0 week</time_frame>
    <description>EKG</description>
  </other_outcome>
  <other_outcome>
    <measure>safety of both groups before treatment as meausred by blood regular test</measure>
    <time_frame>0 week</time_frame>
    <description>Blood regular test</description>
  </other_outcome>
  <other_outcome>
    <measure>safety of both groups before treatment as measured by urine regular test</measure>
    <time_frame>0 week</time_frame>
    <description>Urine regular test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Perimenopause</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Electroacupuncture</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baihui, Yintang, Guanyuan(dual), Zigong(dual), Sanyinjiao(dual), Hegu(dual), Taichong(dual).
Insert needles to the acupoints mentioned above after sterilized.Needle handles of Baihui and Yintang are connected with the electroacupuncture instrument wire. And needle handles of bilateral Zigong are conneted with the electroacupunture instrument wire. And needle handles of bilateral Tianshu are connected with the electroacupunture instrument wire. Density wave, frequency of 10/50Hz and current intensity is 0.5~1.0 mA for 30 minutes. 3 times per week. Each treatment interval of more than 24 hours, continuous treatment for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>escitalopram oxalate tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 hour after breakfast oral taking 10mg escitalopram oxalate tablets, continuous treatment for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>electro-acupuncture</intervention_name>
    <description>8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.
Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5~1.0 mA</description>
    <arm_group_label>Electroacupuncture</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram oxalate tablets</intervention_name>
    <description>escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks</description>
    <arm_group_label>escitalopram oxalate tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Conforms to the diagnosis standard of STRAW-10 for perimenopause, conforms to the
             diagnosis standard of The Diagnostic and Statistical Manual of Mental Disorders, Fifth
             Edition (DSM-5) for depression, and conforms to the diagnosis standard of The
             International Statistical Classification of Diseases and Related Health Problems 10th
             Revision (ICD-10) F32.0(mild depression) or F32.1(moderate depression);

          -  Fisrt attack during perimenopausal period;

          -  HAMD-17 score ＞7 and ＜23;

          -  Age ≥45 to ≤55;

          -  No hormone replacement therapy (HRT) or no antidepressant 3 months before into the
             group;

          -  Sign the consent consent, volunteered for this study

        Exclusion Criteria:

          -  Fail to rule out the possibility of suicide in depression factor of The Symptom
             Checklist (SCL-90);

          -  Application of estrogen, progesterone, selective serotonin reuptake inhibitors
             (SSRIs), soybean isoflavone, vitamin E or black cohosh in recent 4 weeks;

          -  Allergic to citalopram or escitalopram tablets;

          -  Taken the non selective, irreversible inhibitor of monoamine oxidase (MAOIs) in recent
             2 weeks;

          -  Taken linezolid, pimozide, tryptophane,tramadol, triptans or other drugs that may
             cause drug adverse reactions in recent 2 weeks;

          -  Patient with prolongation of the QT interval or congenital long QT syndrome

          -  Taken herbs or products that contain isatin, pilose antler, hawthorn, fleeceflower
             root, common St.John's wort herb, hypericin;

          -  Ovarian dropsy or hysteromyoma with more than 4cm diameter, oophorectomy, or
             hysterectomy;

          -  Mandatory indications of hormonotherapy, such as surgery-induced menopause or
             osteoporosis;

          -  Patient with history of radiotherapy or chemotherapy, or undergoing radiotherapy or
             chemotherapy;

          -  Vaginal bleeding of undetermined origin;

          -  Patient with coagulation disorders, or taking anticoagulants such as Warfarin, or
             heparin;

          -  Patient with skin diseases, such as eczema,or psoriasis;

          -  Serious hepatic insufficiency or serious renal inadequacy;

          -  Uncontrolled hypertension, diabetes, or thyroid disease;

          -  Diabetic neuropathy, or malignant tumor;

          -  Pregnancy intention, in pregnancy or lactation;

          -  Regular use of sedative and anti anxiety drugs;

          -  The long-term smoking and/or drinking;

          -  Having Pacemaker or artificial joint；

          -  Electrolyte is disorder, serious heart disease or other potential life-threatening
             disease patients;

          -  Compliance may be poor or fear of acupuncture.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenbin Fu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guangdong Provincial Hospital of Traditional Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenbin Fu, MD</last_name>
    <email>fuwenbin@139.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhaofeng Li</last_name>
    <email>qdlzfcmd@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbin Fu, MD</last_name>
      <email>fuwenbin@139.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhaofeng Li</last_name>
      <email>qdlzfcmd@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>April 19, 2015</last_update_submitted>
  <last_update_submitted_qc>April 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial Hospital of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Fu Wenbin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 10, 2017</submitted>
    <returned>February 20, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

